Allergan to Buy MAP Pharmaceuticals for $958M

Jan. 22 (Bloomberg) -- Allergan agreed to pay $25 per share for MAP Pharmaceuticals in what the companies called a “definitive merger agreement.” Matt Miller reports on Bloomberg Television's "Bloomberg Rewind." (Source: Bloomberg)

Bob Doll: Rates Are in a Long-Term Bottoming Process
48:29 - Bob Doll, senior portfolio manager at Nuveen Asset Management, looks at the factors behind the current bond selloff as he sees markets recognizing better growth and inflation. He speaks on "Bloomberg Surveillance." (Source: Bloomberg)
  • Novo Nordisk Slashes Long-Term Profit Growth on Pricing
  • Nissan Deal Raises Questions on Trade, Says Lockhart
  • Pound Plummets as U.K. Government Wins Brexit Suit